RBC Capital Reiterates Outperform on Avid Bioservices, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge has reiterated an Outperform rating on Avid Bioservices (NASDAQ:CDMO) and maintained a price target of $8.
July 03, 2024 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Sean Dodge has reiterated an Outperform rating on Avid Bioservices and maintained a price target of $8.
The reiteration of an Outperform rating and the maintenance of a price target at $8 by a reputable analyst can boost investor confidence in Avid Bioservices, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100